192 related articles for article (PubMed ID: 10554102)
1. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
2. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
3. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
5. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
Hanada K; Mukasa Y; Nomizo Y; Ogata H
J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
[TBL] [Abstract][Full Text] [Related]
6. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
7. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
9. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
12. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
13. Calcium blockers enhance cisplatin-induced nephrotoxicity in rats.
Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Kumazawa J
Int Urol Nephrol; 1992; 24(5):549-53. PubMed ID: 1459833
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Uchino H; Matsumura Y; Negishi T; Koizumi F; Hayashi T; Honda T; Nishiyama N; Kataoka K; Naito S; Kakizoe T
Br J Cancer; 2005 Sep; 93(6):678-87. PubMed ID: 16222314
[TBL] [Abstract][Full Text] [Related]
15. Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.
Saad SY; Najjar TA; Noreddin AM; Al-Rikabi AC
Pharmacol Res; 2001 Feb; 43(2):193-8. PubMed ID: 11243722
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
[TBL] [Abstract][Full Text] [Related]
17. Relationship between age and nephrotoxicity following single low-dose cisplatin (CDDP) injection in rats.
Namikawa K; Kinsoku A; Minami T; Okazaki Y; Kadota E; Teramura K; Hashimoto S
Biol Pharm Bull; 1995 Jul; 18(7):957-62. PubMed ID: 7581250
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
